Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cisplatin - concentrate for soln for inf - 0.5 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cisplatin -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cisplatin ebewe is indicated as palliative therapy to be employed as follows: metastatic non-seminomatous germ cell carcinoma: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic non-seminomatous germ cell tumours who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumours: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. advanced and refractory carcinoma of the bladder: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with advanced stage bladder cancer refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. squamous cell carcinoma of the head and neck (refractory to standard chemotherapy): cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with squamous cell carcinoma of the head and neck refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy.

Israel - English - Ministry of Health

abic marketing ltd, israel - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - cisplatin - cisplatin - palliative therapy to be employed either alone, or more commonly in established combination therapy with orher approved chemotherapeutic agents and in patients with metastatic testicular tumor and metastatic ovarian tumor who have alreasy received appropriate surgical and/or radiotherapeutic procedures and in patients with advanced bladder cancer.

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - cisplatin - concentrate for soln for inf - 1 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cisplatin - concentrate for soln for inf - 0.5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

carysfort healthcare limited - codeine phosphate hemihydrate; paracetamol - suppository - 1000 mg/60 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Ireland - English - HPRA (Health Products Regulatory Authority)

carysfort healthcare limited - paracetamol; codeine phosphate hemihydrate - capsule, hard - 500 mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Ireland - English - HPRA (Health Products Regulatory Authority)

carysfort healthcare limited - codeine phosphate hemihydrate; paracetamol - suppository - 500 mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

Canada - English - Health Canada

bayer inc - pseudoephedrine sulfate; loratadine - tablet (immediate and extended release) - 120mg; 5mg - pseudoephedrine sulfate 120mg; loratadine 5mg - second generation antihistamines